Use of Immunosuppression and the Risk of Subsequent Overall or Cancer Mortality in Patients With Noninfectious Ocular Inflammatory Diseases
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Ophthalmology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Use of Immunosuppression and the Risk of Subsequent Overall or Cancer Mortality
Ophthalmology 2023 Dec 01;130(12)1258-1268, JH Kempen, CW Newcomb, TL Washington, CS Foster, L Sobrin, JE Thorne, DA Jabs, EB Suhler, JT Rosenbaum, HN Sen, GA Levy-Clarke, RB Nussenblatt, NP Bhatt, CY Lowder, DA Goldstein, YI Leiderman, NR Acharya, GN Holland, RW Read, JP Dunn, KA Dreger, P Artornsombudh, HA Begum, TD Fitzgerald, S Kothari, AR Payal, E Daniel, SS Gangaputra, RO Kaçmaz, TL Liesegang, SS Pujari, N Khachatryan, A Maghsoudlou, HK Suga, CM Pak, KJ Helzlsouer, JM BuchanichFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.